Immuno-Biological Laboratories Co., Ltd.
4570.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.54 | -0.16 | -1.09 | 0.62 |
| FCF Yield | 2.77% | 2.40% | 0.70% | -3.06% |
| EV / EBITDA | 16.99 | 33.55 | -10.28 | -11.11 |
| Quality | ||||
| ROIC | 12.08% | 6.90% | 4.43% | -7.61% |
| Gross Margin | 64.81% | 63.34% | 66.28% | 58.17% |
| Cash Conversion Ratio | 0.74 | 0.72 | -0.12 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.86% | 8.04% | 9.65% | 3.98% |
| Free Cash Flow Growth | 7.58% | 335.09% | 128.39% | 55.11% |
| Safety | ||||
| Net Debt / EBITDA | -2.74 | -3.89 | 1.14 | 1.10 |
| Interest Coverage | 166.15 | 92.30 | 54.40 | -190.67 |
| Efficiency | ||||
| Inventory Turnover | 1.07 | 0.93 | 0.84 | 0.83 |
| Cash Conversion Cycle | 423.11 | 472.19 | 524.86 | 532.77 |